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Gene therapy with AR isoform 2 rescues spinal 
and bulbar muscular atrophy phenotype by  
modulating AR transcriptional activity
Wooi F. Lim1, Mitra Forouhan1, Thomas C. Roberts1, Jesse Dabney2, Ruth Ellerington1, Alfina A. Speciale1, 
Raquel Manzano2, Maria Lieto2, Gavinda Sangha2, Subhashis Banerjee2, Mariana Conceição, 
Lara Cravo1, Annabelle Biscans3, Loïc Roux2, Naemeh Pourshafie4, Christopher Grunseich4, 
Stephanie Duguez5, Anastasia Khvorova3, Maria Pennuto6,7, Constanza J. Cortes8, Albert R. La Spada9, 
Kenneth H. Fischbeck4, Matthew J.A. Wood1,10†, Carlo Rinaldi1,10*†
Spinal and bulbar muscular atrophy (SBMA) is an X-linked, adult-onset neuromuscular condition caused by an 
abnormal polyglutamine (polyQ) tract expansion in androgen receptor (AR) protein. SBMA is a disease with high 
unmet clinical need. Recent studies have shown that mutant AR-altered transcriptional activity is key to disease 
pathogenesis. Restoring the transcriptional dysregulation without affecting other AR critical functions holds great 
promise for the treatment of SBMA and other AR-related conditions; however, how this targeted approach can be 
achieved and translated into a clinical application remains to be understood. Here, we characterized the role of AR 
isoform 2, a naturally occurring variant encoding a truncated AR lacking the polyQ-harboring domain, as a regu-
latory switch of AR genomic functions in androgen-responsive tissues. Delivery of this isoform using a recombi-
nant adeno-associated virus vector type 9 resulted in amelioration of the disease phenotype in SBMA mice by 
restoring polyQ AR–dysregulated transcriptional activity.
INTRODUCTION
Spinal and bulbar muscular atrophy (SBMA), or Kennedy’s disease, 
is an X-linked, adult-onset neuromuscular disease caused by a CAG 
(cytosine-adenine-guanine) trinucleotide repeat expansion encoding 
a polyglutamine (polyQ) tract in the androgen receptor (AR) (1) 
and affecting 1 in 50,000 men worldwide (2). SBMA is frequently 
misdiagnosed with other neuromuscular diseases (3). In addition, 
recent findings indicate a significantly larger proportion of individuals 
among the general population carrying pathological ranges of polyQ 
disease–associated alleles, including AR, than what expected from 
previous studies (4, 5), overall suggesting that the prevalence of this 
disease is largely underestimated.
AR is a member of the nuclear receptor superfamily, a class of 
transcription factors activated by steroid hormones (6), and is involved 
in several essential physiological processes such as cell growth and 
survival through mechanisms both dependent and independent on 
DNA binding (7). Nuclear receptors share a common three-domain 
structure, comprising an intrinsically disordered N-terminal domain 
(NTD), with potent transcriptional activation or repression capability, 
a central two zinc finger motif DNA binding domain (DBD), and a 
well-conserved C-terminal ligand-binding domain (LBD), responsible 
for ligand recognition (6). Given their modular structure, expression of 
isoforms resulting from alternative splicing or starting and termination 
events has profound effects on nuclear receptor activity and function.
SBMA individuals develop muscle weakness and atrophy as a 
consequence of lower motor neuron and skeletal muscle degeneration 
and usually become wheelchair-bound within 15 to 20 years from 
disease onset (8). Toxicity is dependent on the presence of AR ligand 
testosterone or dihydrotestosterone (DHT), and cell dysfunction and 
death ultimately result from profound alterations of cellular processes 
mainly by a gain-of-function mechanism (9–14). The mutation 
also leads to a partial loss of AR function, which accounts for certain 
aspects of the disease, such as the partial androgen insensitivity 
syndrome frequently observed in patients with SBMA (15, 16). In 
addition to the proteotoxic stress posed by the mutant protein, the 
expanded polyQ tract severely affects AR transcriptional activity, 
with significant alterations of expression of genes containing the 
androgen-responsive element (ARE) motif (10, 13, 14).
Previous studies in a Drosophila model of SBMA have shown 
that interaction between the AR and its transcriptional coregulators 
through the AR activation function 2 (AF2) domain and binding of AR 
to target genes are both required to start the disease (17). A therapeutic 
approach that is able to selectively modulate polyQ AR transcriptional 
dysregulation, without interfering with other AR critical functions, 
holds great promise for the treatment of SBMA and is not currently 
available. Despite recent advancements of the understanding of disease 
mechanisms, to this date, SBMA remains a condition with high 
unmet clinical need. The use of antiandrogens has shown marginal 
benefits in phase 2 trials (18) and no definite amelioration of the motor 
functions in patients in larger, multicenter randomized-controlled 
trials (19, 20). AR-silencing strategies have shown encouraging 
results in preclinical models but are hampered by the risks of 
long-term, widespread AR loss (21). Alternatively, small molecules that 
1Department of Paediatrics, University of Oxford, Oxford, UK. 2Department of Physiology, 
Anatomy and Genetics, University of Oxford, Oxford, UK. 3RNA Therapeutics Institute, 
University of Massachusetts Medical School, Worcester, MA, USA. 4Neurogenetics 
Branch, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, 
USA. 5Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research 
Institute, Londonderry, UK. 6Department of Biomedical Sciences, University of Padova, 
Padova, Italy. 7Venetian Institute of Molecular Medicine (VIMM), Padova, Italy. 8Depart-
ment of Neurology, Duke Center for Neurodegeneration and Neuro therapeutics, Duke 
University School of Medicine, Durham, NC, USA. 9Departments of Pathology 
and Laboratory Medicine, Neurology, and Biological Chemistry and the UCI Institute 
for Neurotherapeutics, University of California, Irvine, Irvine, CA, USA. 10MDUK Oxford 
Neuromuscular Centre, University of Oxford, Oxford, UK.
*Corresponding author. Email: carlo.rinaldi@paediatrics.ox.ac.uk
†These authors contributed equally to this work as senior authors.
Copyright © 2021 




for the Advancement 
of Science. No claim to 
original U.S. Government 
Works. Distributed 
under a Creative 
Commons Attribution 









Lim et al., Sci. Adv. 2021; 7 : eabi6896     20 August 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
2 of 15
modulate AR coregulator–binding affinity are an attractive therapeutic 
avenue (22–24). Nevertheless, the lack of full understanding of their 
mechanisms of action, potential off-target effects, and unfavorable 
pharmacokinetic profiles limits their clinical applicability.
In our study, we establish a physiological role of one of the naturally 
occurring AR isoforms, i.e., AR isoform 2 (AR-2), in fine-tuning 
full-length AR transcriptional activity. Furthermore, by selectively 
targeting mutant AR transcriptional dysregulation, we provide 
proof-of-principle evidence for efficacy and safety of a gene therapy 
strategy based on delivery of this AR variant to treat SBMA, confirming 
the translational potential of this strategy.
RESULTS
AR-2 isoform gene expression profiling in human tissues
We first sought to determine the physiological expression levels of 
AR isoforms in human tissues that are relevant to SBMA pathogenesis. 
From our deep RNA sequencing (RNA-seq) data (~100 million per 
reads), obtained from DHT-treated induced pluripotent stem (iPS) 
cell–derived motor neurons (n = 3 control lines, n = 3 SBMA lines) 
and postmortem human medial and lateral motor cortexes, as well 
as cervical and lumbar spinal cords (n = 6 controls, n = 1 SBMA for 
each), we identified nine alternative AR transcripts expressed at low 
levels and encoding isoforms with various exon combinations 
(Fig. 1, A and B). Of these, AR-2 (ENST00000396043.2; CCDS43965.1) 
uniquely arises from the use of an alternative transcription start site 
(TSS) downstream of AR-1 TSS, and inclusion of exon 1b, located 
22.1-kb downstream of exon 1 (Fig. 1A) (25). Similar distribution of 
alternatively spliced AR isoforms was observed for RNA-seq from 
iPS-derived motor neurons of SBMA individuals with or without 
DHT (Fig. 1A and fig. S1A). AR-2 accounts for an average of 17.4% 
of the AR isoforms in human brain (Fig. 1B). In a comprehensive 
human cDNA array, the highest relative AR-2 expression was found 
in prostate and skeletal muscle, which are androgen-responsive 
tissues (Fig. 1C). AR-2 transcript levels were higher than canonical 
AR-1 in human myoblasts from patients with SBMA and sex- and 
age-matched controls with no difference between the two groups 
(Fig. 1D). This chromatin locus is functionally accessible and actively 
transcribed, as indicated by increased deoxyribonuclease I hyper-
sensitivity in 125 different cell types and transcription factor 
occupancy around exon 1b [from Encyclopedia of DNA Elements 
(ENCODE) projects] (fig. S2A) and RNA polymerase II enrichment 
relative to a downstream intronic sequence, assayed by chromatin 
immunoprecipitation (ChIP) (Fig. 1E). Multiple sequence analysis 
of exon 1b and the flanking regions suggest a close to 100% homol-
ogy with Rhesus macaque and poor conservation in Mus musculus 
and Rattus norvegicus, where a stop codon downstream of the start 
codon infers that AR-2 isoform is not present in these species 
(fig. S2A) (26). The encoded protein contains a unique seven–amino 
acid sequence in the N terminus in place of the canonical NTD 
(Fig. 1F) and has a molecular mass of 45 kDa, hence the designated 
name AR45 (Fig. 1G). AR45 is expressed both in the cytoplasm and 
nucleus of human myoblasts, engineered to express the endogenously 
tagged AR45 protein, where an in-frame FLAG tag was inserted 
5′ of the AR-2 gene by CRISPR-Cas9 method (Fig. 1H).
AR45 regulates AR transcriptional activity
We next went on to characterize the role of AR45 on both wild-type and 
mutant AR biology. AR45 alone was not able to activate transcription 
of a luciferase reporter containing the AR-regulating prostate- 
specific antigen promoter (Fig. 2A). AR45 overexpression led to 
suppression of transactivation of both wild-type and mutant full-
length AR in a dose-dependent manner (Fig. 2, A and B), an effect 
that was abolished by introducing a DBD-inactivating substitution 
A574D into the AR45 transgene (Fig. 2A), suggesting that the effect 
of AR45 on AR transactivation is specific and requires binding to 
DNA. AR dimerization through N/C-terminal interactions via the 
FxxLF motif and DBD/DBD interactions via the dimerization box 
(D-box) is a necessary step to activate the transcription of AR target 
genes (27). Since the DBD and LBD are conserved in AR45, we 
hypothesized that AR can also form heterodimers with AR45. We 
tested this hypothesis by using a bioluminescence resonance energy 
transfer (BRET) assay, which allows real-time detection of protein- 
protein interactions by exploiting the naturally occurring phenomenon 
of energy transfer from a donor enzyme to an acceptor fluorophore 
following enzyme-mediated oxidation of a substrate (28). All com-
binations of N- and C-terminal fusion constructs (fig. S3A) were trans-
fected into AR-null cells, and one of the combinations exhibiting the 
highest BRET signal was chosen for further analysis (fig. S3B). BRET 
saturation curve indicated specific interaction between AR45 and 
full-length AR (fig. S3C). AR45 also interacts with full-length mutant 
AR (AR55Q). Mutation in the FxxLF motif (F-mut: F23, 27A/L26A) 
or N terminus of this motif (G21E) and not the D-box motif (D-mut: 
A596T/S597T) inhibited the AR/AR45 dimerization (Fig. 2C). We 
also found that AR45 forms homodimers (figs. S3D and S4E). The 
AR/AR45 interaction was further validated by co-immunoprecipi-
tation (co-IP) (fig. S4A). AR protein levels were not affected by the 
presence of AR45 in a cycloheximide chase experiment, suggesting 
that AR45 does not alter AR protein turnover (fig. S4, B and C).
To gain insight into endogenous AR45 functions, we next pro-
filed global gene expression changes via RNA-seq in DHT-treated 
human myoblasts where AR-2 transcript was knocked down (KD) 
compared to control cells treated with a nontargeting siRNA. We 
first designed an array of 11 small interfering RNAs (siRNA), spanning 
exon 1b sequence (fig. S5A). To improve their pharmacokinetic 
properties, these siRNAs were fully chemically modified and lipid- 
conjugated (29). These siRNAs resulted in selective silencing of 
endogenous AR-2 (ranging from 45 to 90%) (fig. S5B). AR-2 KD in 
human myoblasts using the best-performing siRNA was confirmed by 
reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) 
before RNA-seq (fig. S6A). Using differential expression analysis 
(DEseq; P < 0.05, fold change >1.5), we identified 148 genes that 
were differentially expressed upon AR-2 KD with higher proportion 
of up-regulated genes (59%) (table S1). Of the differentially expressed 
genes, 32% were found to contain an ARE sequence in the promoter 
region (Fig. 2D and table S1). Gene set enrichment analysis (GSEA) 
showed up-regulation of genes associated with AR and estrogen 
response (Fig. 2E). Among the ARE-containing genes, endoge-
nous AR-2 KD resulted in up-regulation of NFE2L1 (Nuclear factor, 
erythroid 2 like 1), a master regulator of proteasome subunits, and 
down-regulation of HSPA8 (Heat shock protein family A member 8), 
a member of the chaperone-assisted selective autophagy complex, 
suggesting that AR45 may be involved in the regulation of androgen- 
induced cell stress signals (Fig. 2F) (30, 31).
To investigate whether AR and AR45 co-occupy the same genomic 
loci, we carried out ChIP analyses at the promoter regions of GREB1, 
ZNF485, and EHF, which are known as AR direct target genes (fig. 
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Fig. 1. Gene expression profiling of the AR-2 isoform. (A) Sashimi plot depicting alternative isoforms for the AR gene generated from RNA-seq data in iPS-derived 
motor neurons from unaffected (control) and SBMA individuals. The number in the line represents the reads crossing a particular splice junction (curved lines). A scheme 
showing AR-1 (blue), AR-2 (red), and the other annotated AR isoforms is shown below. (B) Nested pie chart shows the proportion of mRNA AR isoforms levels from 
postmortem human tissues expressed as log-normalized counts. Percentage range for each isoform is in the parenthesis. (C) Heatmap indicating relative AR-2 transcript 
levels in human tissues normalized to GAPDH. (D) Relative mRNA expression levels normalized to GAPDH of AR-2 compared to AR-1 in human myoblasts from SBMA and 
unaffected subjects. (E) Chromatin immunoprecipitation (ChIP) from AR45-transfected MCF7 cells using anti–Pol II antibody shows increased occupancy on exon 1b of 
AR gene compared to a downstream sequence. (F) AR and AR45 protein domain conservation is shown. H, Hinge domain. Amino acid numbers refer to full-length (FL) 
human AR. Sequence of AR45 NTD is shown in the magnification. (G) Immunoblotting using an anti–C-terminal AR antibody of human embryonic kidney (HEK) 293 whole 
cell lysates where AR or AR45 was overexpressed. Size corresponding to the two isoforms (arrows) is expressed in kilodalton and displayed next to the protein marker. 
(H) Immunofluorescence micrographs of DHT-treated unmodified (control) or expressing endogenous FLAG-tagged AR45 (FLAG-AR45) human myoblasts. Cells were stained 
with anti-FLAG antibody (red), anti-laminin antibody (LAM; white), and 4′,6-diamidino-2-phenylindole (DAPI) (blue). Arrowheads indicate the AR45 signal. Scale bars, 20 m. 
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Fig. 2. AR45 regulates AR transcriptional activity. (A) AR transactivation, expressed as relative luciferase unit (RLU), was measured in HEK293T cells transfected with 
vectors expressing FL AR or AR45, and pARE-E1b-Luc and -galactosidase pCMV reporter constructs. (B) AR transactivation was measured in HEK293T cells expressing 
AR FL alone or with increasing concentration of AR45 (0.25, 0.5, and 1 g). (C) AR45 and AR interaction was measured in HEK293T cells by bioluminescence resonance 
energy transfer (BRET) and expressed as milliBRET units (mBU). (D) Pie chart shows the proportion of up-regulated (58%; red) and down-regulated (42%; blue) genes 
containing ARE in their promoters among the differentially expressed transcripts upon AR45 knockdown (AR45 KD) in human myoblasts. (E) Gene set enrichment analysis 
(GSEA) using the Molecular Signature Database showing up-regulated (red) and down-regulated (blue) pathways upon AR45 KD. UV, ultraviolet; MTORC1, mechanistic 
target of rapamycin complex 1; G2M, G2 to M phase. (F) Heatmap of variance- stabilized RNA-seq read counts (z score) of ARE-containing transcripts. NTC, nontargeting 
control. (G) ChIP from FLAG-AR45–expressing MCF7 cells with anti-FLAG antibody or immunoglobulin G (IgG) isotype control. EtOH, ethanol. (H) mRNA expression 
levels normalized to GAPDH of known ARE-containing genes in DHT-treated AR45- overexpressing MCF7 cells. GREB1, growth regulating estrogen receptor binding 1; 
ZNF485, zinc finger protein 485; EHF, ETS homologous factor. (I) MCF7 cells nuclear extracts were subjected to IP using an anti–N-terminal AR antibody and immunoblot-
ted for BRD4, AR, and AR45. One percent total lysate was used as input. Size is expressed in kilodalton and displayed next to the cropped blots. IB, immunoblot. (J) mRNA 
expression levels of known AR/BRD4 coregulated genes normalized to GAPDH in MCF7 cells upon treatment with DHT and bromodomain inhibitor JQ1 (500 nM) or AR45. 
ERG, ETS-related gene. (K) Working model: In addition to forming AR:AR homodimers, AR also heterodimerizes with its shorter isoform AR45, resulting in modulation of 
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(FL-AR45) upon DHT treatment (Fig. 2G), indicating AR45 occu-
pancy at the AR binding sites. Overexpression of AR45 resulted in 
reduced transactivation of those targets (Fig. 2H).
To elucidate the underlying mechanism of the effect of AR45 on 
AR transcriptional activity, we investigated whether overexpression 
of AR45 affects the interaction between AR and its transcriptional 
coregulators. In a co-IP assay in human breast cancer MCF7 (Michigan 
Cancer Foundation-7) cells, we demonstrated that AR45 reduces 
binding affinity between AR and the master transcriptional regulator 
BRD4 (Bromodomain-containing protein 4) (Fig. 2I and fig. S8A). 
Treatment of these cells with 500 nM JQ1, a selective small-molecule 
BRD4 inhibitor, recapitulated the decreased expression of AR target 
genes observed with AR45 overexpression, further validating the 
functional relevance of this finding (Fig. 2J). Together, these results 
demonstrate that AR45 forms heterodimers with both wild-type and 
mutant AR and modulates AR genomic activity by reducing binding 
to its transcriptional coregulators (Fig. 2K).
Viral delivery of AR45 ameliorates the disease phenotype 
in a mouse model of SBMA
On the basis of previous studies showing that AR binding to its 
target genes through the DBD is critical to SBMA pathogenesis (17) 
and that disrupting the interaction between AR and its transcriptional 
coregulators represents a promising therapeutic strategy for this 
disease (17, 22, 23, 33), we reasoned that overexpression of AR45 
would be able to counteract SBMA toxicity.
We generated two adeno-associated viruses (AAVs) carrying 
single-stranded AAV9 vectors encoding either FL-AR45 cDNA driven 
by the ubiquitous elongation factor 1 (EF1) promoter and enhanced 
green fluorescent protein (eGFP) driven by cytomegalovirus (CMV) 
promoter (AAV9-AR45) or eGFP only (AAV9-control) (Fig. 3A). 
The SBMA model chosen for the study expresses the human AR 
transgene with 100 glutamine residues (AR100Q) and recapitulates 
the main features of the SBMA phenotype, with androgen-dependent 
muscle atrophy, reduced grip strength, denervation, and shortened 
survival, starting at 7 weeks of age (34). Notably, protein levels 
of monomeric human AR in the skeletal muscle and spinal cord of 
these mice are comparable to the wild type’s (34). On the basis of 
quantitative measures of body weight, we performed a statistical 
power analysis to establish the minimum number of mice required 
for each cohort in the trial (Cohen’s d effect size: 0.8; minimum sample 
size for each group: 10 mice). Male transgenic SBMA mice were 
blindly randomized to receive one of the two AAVs by single tail-vein 
injection at 5 weeks of age, at a dose of 2 × 1011 to 2.5 × 1011 vector 
genomes (vg), in two experiments, aimed at assessing phenotypic/
functional (n = 15) and histopathological/molecular (n = 3) differences 
between the two groups (Fig. 3B). For translational relevance, the 
timing of injection was chosen so that the peak of transgene expression 
matched the appearance of the disease manifestations in this model 
(35). In quadriceps muscle tissues collected 6 weeks after injection, 
we observed ~60% GFP-positive fibers and AR45 staining in the 
treatment group, indicating efficient viral transduction (Fig. 3C). 
Relative expression of viral-delivered AR45 mRNA in lumbar spinal 
cord was ~4 times lower than quadriceps muscle (Fig. 3D), consist-
ent with reduced central nervous system transduction after peripheral 
injection of single-stranded AAV9 vectors in adult mice (fig. S9) 
(36). AR45 treatment significantly prolonged the life span of these 
mice from a median of 87 to 102 days (primary outcome measure; 
Fig. 3E) and delayed the disease onset by 12 days, determined as the 
age at which the mice start losing body weight (Fig. 3, F and G). 
Notably, AR45 overexpression reduced end-of-study body weight 
loss (Fig. 3H and fig. S10A) and improved rotarod activity (Fig. 3I) and 
rear grip strength (Fig. 3J and fig. S10B). Together, these findings 
demonstrate that viral delivery of AR45 ameliorates the disease 
phenotype in SBMA mice.
AR45 treatment restores the pathologic degeneration 
and transcriptional profile in SBMA mice without  
decreasing inclusion accumulation
To further characterize the effects of AR45 treatment on SBMA, 
quadriceps muscles from 11-week-old SBMA mice treated with 
AAV9-AR45 or AAV9-control, and wild-type littermates were 
collected for histopathological analyses. Staining of quadriceps muscle 
cross sections with hematoxylin and eosin (H&E) and nicotinamide 
adenine dinucleotide (NADH) showed a marked amelioration of 
the muscle architecture, with reduced angulated myofibers, grouped 
atrophic fibers, enlarged fibers with central nuclei (Fig. 4A), and 
increased mean cross-sectional myofiber areas (Fig. 4B). Furthermore, 
we observed marked reduced colocalization of neural cell adhesion 
molecule (NCAM)/polysialic acid–NCAM (P-NCAM) staining, in-
dicating decreased denervation/re-innervation activity, in AR45- 
treated SBMA mice compared to transgenic controls (Fig. 4, C and D). 
To explore whether AR45 treatment restores the disease-related 
transcriptional dysregulation, we performed RNA-seq in tibialis an-
terior (TA) muscle from 11-week-old transgenic male mice treated 
with AAV9-AR45 or AAV9-control and wild-type littermates.
We identified 6644 significantly dysregulated genes in SBMA 
skeletal muscle compared to wild type (3354 up-regulated and 3290 
down-regulated) (fig. S11A and table S2), with changes in genes 
involved in several functions, including mitochondrial homeostasis, 
lipid metabolism, glycolysis, p53 signaling, and DNA repair, as 
revealed by the functional network and pathway annotation (fig. S11B). 
These alterations overlap with published transcriptomic profiles 
using other SBMA models (37–40). Notably, AR45 treatment resulted 
in significant restoration of 27 of the 32 down-regulated (84%) and 
5 of the 17 up-regulated (29%) SBMA hallmark molecular signatures 
(Fig. 4E), with gene expression clusters showing a pattern toward 
normalization (fig. S11C and table S3). Treatment did not affect 
serum testosterone concentrations in mice (fig. S12A). In addition, 
no change in human or mouse AR mRNA and protein levels (fig. 
S12, B to D), as well as in the polyQ-positive inclusions and ubiquitin 
staining in both spinal cord (Fig.  4,  F  and  G, and fig. S13A) and 
skeletal muscle (Fig. 4, H and I, and fig. S13B), was observed upon 
AR45 overexpression, supporting a model where therapeutic benefit 
can be achieved independently of polyQ AR aggregation.
Systemic delivery of AAV9-AR45 vector did not induce 
detectable toxicity in SBMA mice
To investigate the potential undesirable effects of both viral vector 
and AR45 transgene overexpression on vital physiological functions, 
we used the bacterial artificial chromosome (BAC) SBMA transgenic 
mouse model, which develops a very mild neuromuscular phenotype, 
unsuitable for proof of concept studies but, by harboring the entire 
length of the human AR locus (41, 42), uniquely expresses AR45 at 
physiological levels. Using the same treatment paradigm adopted 
for the efficacy study, 5-week-old male mice were injected by tail 
vein with AAV9-AR45 or AAV9-control, at a dose of 2 × 1011 to 
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this model (41). Copy number analysis per nanogram of total RNA 
in four mice revealed an average of 20.2% increase of AR45 expression 
over endogenous levels in TA muscle and 7.5% in lumbar spinal cord 
upon treatment with AAV9-AR45 vector (Fig. 5A) and highest vg 
concentration in the liver and spleen relative to the skeletal muscle 
(Fig. 5B), consistent with previous studies evaluating AAV9 trans-
duction properties in vivo (43).
Histopathologic analysis of the heart, spleen, liver, skeletal muscle, 
kidney, brain, and testis revealed no adverse macroscopic findings. 
We did not observe increased infiltration of F4/80- expressing mac-
rophages (Fig. 5, C and D) in the liver of SBMA mice treated with 
AAV9-control or AAV9-AR45 compared to wild-type littermates. 
A mild elevation in Il-1 and Tnf- mRNA levels was observed in 
tissues of SBMA mice (Fig. 5E), further confirming a role of AR in 
transcriptionally inducing an inflammatory response (44). Notably, 
AR45 treatment normalized this effect (Fig. 5E). To assess whether 
the treatment results in chronic inflammation and fibrosis, we ana-
lyzed transcripts levels of critical markers (Sma, Fibronectin, Col3a1, 
and Gli1), which were unchanged in treated SBMA mice compared 
to untreated wild-type littermates (Fig. 5E). Collectively, these 
data suggest the lack of deleterious effects against the AAV9 or the 
AR45 transgene.
Fig. 3. AAV9-mediated delivery of AR45 improves the SBMA phenotype. (A) Schematic representation of AAV vectors used in this study. AAV inverted terminal 
repeats (ITR) and SV40 poly-adenylation signal (triangles) are also indicated. (B) Experimental design; arrow indicates the timing of the intravenous (i.v) injection. Dose is 
expressed as vector genomes (vg). (C) Representative images of skeletal muscle from SBMA mice treated with AAV9-AR45 or AAV9-control, stained with FLAG antibody 
(red), LAM (white), GFP (green), and DAPI (blue). Arrowheads indicate AR45 signal. Scale bars, 100 m (merged) and 10 m (inset). (D) AR45 mRNA expression levels 
normalized to GAPDH in spinal cord relative to quadriceps muscle of treated SBMA mice. (E) Kaplan-Meier survival estimation of SBMA mice treated with AAV9-control or 
AAV9-AR45 (M, median; log-rank test). Survival of wild-type mice is shown for reference. (F and G) AR45-treated SBMA mice show a delay in the disease onset by 12 days 
in average (M, median; log-rank test) compared to their SBMA littermates. (H) Weight loss is significantly reduced in AR45-treated SBMA mice. Weights for each mouse at 
the beginning and end of the study are shown in gray (AAV9-control) and pink (AAV9-AR45). (I) Rotarod performances, expressed as latency to fall, are compared between 
treatment groups [two-way analysis of variance (ANOVA)]. Performances of wild-type mice are also shown for reference. (J) Average percentage reduction in grip strength 
at the end of the study (week 13) compared to disease onset (week 8) in SBMA mice treated with AAV9-control and AAV9-AR45 is displayed. Data in (D), (F), (I), and (J) are 
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Fig. 4. AR45 treatment restores the SBMA-associated degeneration in mice. (A) Representative cross sections of gastrocnemius muscle from 11-week-old wild-type 
and SBMA mice treated with AAV9-control or AAV9-AR45. Sections were stained with H&E and NAD/NADH for muscle morphology. Arrows indicate atrophied myofibers. 
Arrowheads indicate myofibers containing centralized nuclei. Scale bars, 100 m. (B) Relative frequency distribution of myofiber cross-sectional diameter size sorted in 
wild-type, control treated-, and AR45-treated SBMA mice. (C) Representative cross sections of gastrocnemius muscle from 11-week-old SBMA mice treated with AAV9-control 
or AAV9-AR45 stained with neural cell adhesion molecule (NCAM) antibody, polysialic acid–NCAM (P-NCAM) antibody, and DAPI. Scale bars, 100 m. (D) Quantification of 
P-NCAM/NCAM colocalized regions relative to the total number of nuclei is graphed. Quantification was performed from a total of six fields for all groups, three mice per 
treatment group. (E) Heatmap shows the normalized enrichment scores (NES) of gene sets significantly enriched at P < 0.05 and false discovery rate ≤ 0.25 in the tibilias 
anterior muscle of AR45-treated compared to control SBMA mice with overexpressed gene sets in red and underexpressed gene sets in blue. Thirty-two pathways were 
partially restored upon AR45 overexpression. (F) Representative cross sections of lumbar spinal cord and (H) gastrocnemius muscle from 11-week-old wild-type and 
SBMA mice treated with AAV9-control or AAV9-AR45, stained with 1C2 antibody and hematoxylin. Scale bars, 100 m. (G and I) Quantification of the number of 1C2-positive 
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Fig. 5. Systemic delivery of AAV9-AR45 did not induce detectable toxicity in mice expressing AR-2 at endogenous levels. (A) Ratios of exogenous (exo) to endogenous 
(endo) AR45 mRNA copy number per ng of total RNA in TA muscle and lumbar spinal cord of four SBMA BAC transgenic mice 5 weeks after treatment with AAV9-AR45 
(1011 vg) are shown. (B) mRNA expression levels of exogenous AR45 in tissues of mice treated with AAV9-AR45 normalized to GAPDH housekeeping gene and expressed 
as fold change to levels in TA muscle are shown. Data are means ± SEM. Each dot represents one replicate (n = 3). (C) Representative cross sections of liver from adult wild-type 
and SBMA BAC transgenic mice treated with AAV9-control or AAV9-AR45 stained with F4/80 antibody and DAPI. Arrowheads indicate the F4/80 positive cells. Scale bars, 
100 m (low magnification) and 10 m (high magnification). (D) Number of F4/80-positive cells per 100 cells is graphed. Quantification was performed from a total of six 
fields for all groups, three mice per treatment group. (E) mRNA expression levels of inflammatory and fibrotic marker genes in tissues from wild-type and SBMA BAC 
transgenic mice treated with AAV9-control or AAV9-AR45 normalized to GAPDH housekeeping gene and expressed as fold change to levels in the respective wild-type 
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DISCUSSION
AR-mediated transcription is dependent on coregulatory proteins 
to recruit transcriptional machinery, increase chromatin accessibility, 
and enhance transactivation (45). PolyQ AR–altered genomic activity 
has been shown to be essential to trigger disease pathogenesis in 
SBMA (17). Therapeutic strategies selectively targeting mutant AR 
transcriptional dysregulation by modulating the actions of coregulators, 
without affecting other critical nongenomic functions of AR, have a 
competitive advantage over existing approaches, which are yet to be 
translated into a treatment for patients with SBMA. Multiple nuclear 
receptor isoforms arise from a single gene by alternative splicing or 
by the use of alternative promoters in health and disease to regulate 
their genomic and nongenomic activities, and AR is no exception 
(46). Pathological AR protein variants, yielding from gene alterations 
and abnormal splicing patterns, have been identified in human 
prostate cancer (47, 48) and have been shown to confer resistance to 
androgen therapies (48, 49), providing opportunities for the identi-
fication of promising therapeutic targets and prognostic markers 
(50–52). Naturally occurring AR isoforms in healthy tissues are less 
well characterized. Here, we have identified nine alternative tran-
script AR variants in iPS-derived motor neurons and human brains. 
Of these, AR-2 appears to be the most abundantly expressed, resulting 
from inclusion of the alternative exon 1b, located in intron 1 of the 
AR gene, and encoding a truncated AR variant with a unique seven–
amino acid peptide in place of the canonical NTD harboring the 
polyQ stretch, 45 kDa in size, hence the name AR45 (25). AR45 was 
previously found to be widely expressed in human tissues to interact 
with AR in two-hybrid assays and inhibit proliferation when 
overexpressed in prostate cancer LNCaP (Lymph Node Carcinoma 
of the prostate) cells (25). Our study—by using deep RNA-seq to 
provide quantitative expression profiles in human tissues, assessing 
the transcriptome-wide effects of AR-2 silencing, and measuring the 
protein-DNA interaction by ChIP assay at ARE sites—significantly 
expands on these findings, supporting a model where AR45 acts as 
an endogenous modulator of AR transcriptional activity. Overex-
pression of AR45 in cells resulted in reduced transactivation of 
ARE-containing AR target genes in a dose-dependent manner by 
reducing AR binding to its transcriptional coactivator BRD4. BRD4, 
a member of the bromodomain and extraterminal (BET) protein 
family, is a master transcriptional and epigenetic regulator that plays 
a pivotal role during several processes from embryogenesis to cancer 
development. Upon interaction with chromatin-associated tran-
scription factors, BRD4 is recruited to hyperacetylated histone 
regions along the chromatin and promotes transcription initiation 
and elongation (53–55). By physically interacting with AR NTD, 
BRD4 plays a critical role in facilitating AR-mediated transcription 
(56, 57); clinical evaluation of BET inhibitors is currently underway 
in castration-resistant prostate cancer (clinical trial: NCT03035591).
These findings prompted us to test delivery of this isoform to 
treat SBMA via AAV9. This viral vector is the serotype of choice to 
transduce neurons and skeletal muscle (58).
To simulate a trial in early disease–stage patients, mice were 
treated at 5 weeks of age with a single-stranded genome AAV9 
vector (2 × 1011 vg): Because of the rate-limiting step involving the 
de novo synthesis of the second DNA strand, this treatment regimen 
results in a 2-week-delayed transgene expression, corresponding to 
the appearance of disease manifestations in this model, as previously 
documented (34, 35). Consistent with previous biodistribution studies 
after peripheral intravascular delivery of AAV9 vectors in adult 
mice (36), we observed extensive transduction in skeletal muscle, 
with fourfold-reduced transgene levels in lumbar spinal cord 6 weeks 
after treatment. Scaling this dose up to improve neuronal transduction 
for human testing would represent a manufacturing challenge and 
may result in a significantly increased risks of liver toxicity in patients, 
as emerged in clinical trials using high dose of AAV8 (3 × 1014 vg/kg) 
to deliver Audentes Therapeutics’ AT132 for patients with X-linked 
myotubular myopathy (59) (clinical trial: NCT03199469). Notably, 
in the last two decades, an increasing number of observations 
derived both from preclinical and clinical studies have indicated that 
skeletal muscle is a primary driver of SBMA pathogenesis (16, 60–66). 
Furthermore, skeletal muscle–specific excision of polyQ AR in a 
BAC mouse model featuring a floxed AR first exon is sufficient to 
prevent the development of disease manifestations (41), and 
peripherally administered treatments that do not cross the blood-brain 
barrier are able to ameliorate the neuromuscular phenotype in mice 
(21, 64, 67), overall suggesting that muscle is a target for therapy 
development in SBMA (68).
More than 120 gene therapy clinical trials using AAV-based 
vectors are currently in use in numerous gene therapy clinical trials, 
ranging from hemophilia to inherited blindness, with reports of 
benefit for patients and favorable safety profiles with a transient and 
asymptomatic hepatitis as the most severe side effect. In 2019, the 
U.S. Food and Drug Administration approved AveXis’ ZOLGENSMA 
(Onasemnogene abeparvovec) for the treatment of patients less than 
2 years of age with spinal muscular atrophy using an AAV9 vector 
at 1.1 × 1014 vg/kg by intravascular administration (clinical trials: 
NCT02122952, NCT 03306277, NCT03421977, and NCT03505099), 
paving the way for the development of AAV-based therapeutics for 
other neuromuscular conditions.
By characterizing the role of a naturally occurring AR isoform in 
AR homeostasis, here we provide proof-of-principle evidence of 
efficacy and safety of a gene therapy strategy based on AAV9-mediated 
delivery of the AR variant AR45 in SBMA mice, with high potential 
to be translated into a treatment for patients. The slightly less notable 
therapeutic effect observed, compared with previously published 
repeated systemic antisense oligonucleotide administrations (21), 
could be partly attributed to the more severe SBMA models used in 
this work and to the low AAV9 dose used for single peripheral 
injection. Before bringing this strategy into clinical testing, many 
aspects of AAV biological properties, which cannot be accurately 
predicted in preclinical studies, such as vector immunogenicity, 
therapeutic potency, duration of expression, and potential toxicity, 
will have to be further elucidated (69), particularly in the context of 
adult-onset neuromuscular diseases, progressing over the course of 
years, like SBMA. Given the critical importance of AR transcriptional 
control in various diseases such as androgen insensitivity syndrome, 
benign prostatic hyperplasia, and prostate cancer (70), intriguingly, 
this isoform may potentially be a target for therapy not only for 
SBMA but also for other AR-related conditions.
MATERIALS AND METHODS
Mice
Experiments were carried out in the Biomedical Sciences Unit, 
University of Oxford according to procedures authorized by the 
U.K. Home Office (Animal Scientific Procedures Act 1986). Mice 
were housed in individually ventilated caging systems, with access 
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analyses. AR100Q (71) and BAC AR121Q (41) transgenic animals 
were provided by the Pennuto laboratory and the La Spada laboratory, 
respectively. Dual promoter AAV vector plasmids containing an 
expression cassette consisting of a human EF1 promoter followed 
by AR45 cDNA or mock sequence and human CMV promoter 
followed by cDNA-encoding GFP were provided by SignaGen 
Laboratories (Rockville, MD). A viral load of 2 × 1011 vg was injected 
into the tail veins of SBMA AR100Q mice. Injection volume was 
brought to 100 l with 1× phosphate-buffered saline (PBS). The 
body weight, rotarod, and grip strength using hanging wire and 
strength meter (Bioseb) were recorded weekly. Randomization was 
performed among littermates, the treatments were administered, 
and analyses were performed by blinded investigators. Study end-
point is set at a body weight loss of >20%.
Cell lines and reagents
Human embryonic kidney (HEK) 293T and MCF7 cells were obtained 
from the American Type Culture Collection (ATCC) and cultured 
as described on the ATCC cell culture guide. Immortalized human 
myoblast cells (MRC CNMD Biobank London, L954/1284 M-I) were 
maintained in skeletal muscle cell growth medium (PromoCell) 
supplemented with supplement mix (PromoCell), 10% (v/v) fetal 
bovine serum (FBS; Gibco), 1× GlutaMAX (Gibco), and 1× antibiotic 
antimycotic (Gibco). iPS cells were cultured and differentiated into 
motor neuron–like cells in the Fischbeck laboratory, as described 
previously (72). All cell lines were cultured at 37°C and 5% CO2. 
AR induction was performed by addition of DHT (Sigma-Aldrich) 
to a final concentration of 10 nM in the respective cell culture medium. 
An equal volume of ethanol was added for the uninduced controls.
Human samples
Anonymized brain tissues (CGND_HRA_00063, CGND_HRA_00218, 
CGND_HRA_00224, CGND_HRA_00035, CGND_HRA_00236, 
CGND_HRA_00399, CGND_HRA_00400, CGND_HRA_ 
00402, CGND_HRA_00411, CGND_HRA_00412, CGND_HRA_00654, 
CGND_HRA_00655, CGND_HRA_00657, and CGND_HRA_00091) 
were provided by the Target ALS Post-Mortem Tissue Core. These 
samples were acquired through various Institutional Review Board 
protocols from member sites and transferred to the New York 
Genomic Consortium in accordance with all applicable foreign, 
domestic, federal, state, and local laws and regulations for processing, 
sequencing, and analyses.
Plasmids construction
To generate different constructs of AR FL (12Q), AR FL (55Q), and 
AR45, we PCR-amplified the AR FL (12Q), AR FL (55Q), and AR45 
cDNAs from their respective expression construct and cloned the 
PCR amplicons separately into a mammalian expression vector under 
the control of the CMV promoter with or without an N-terminal 
FLAG epitope tag. To generate NanoBRET fusion constructs, these 
PCR amplicons were cloned separately into pFN21A HaloTag CMV 
Flexi, pFC14K HaloTag CMV Flexi, pFN31K Nluc CMV-neo Flexi, 
and pFC32K Nluc CMV-neo Flexi vectors via Sgf I and Pme I or Sgf I 
and Eco ICRI following the manufacturer’s protocol (Promega). The 
mutant constructs with mutations at the FxxLF motif (F23,27A/L26A) 
or (G21E), at the D-box (A596T/S597T), or at the DBD (A574D) of AR 
were generated by site-directed mutagenesis using the Q5 Site- 
Directed Mutagenesis Kit (New England BioLabs). All plasmids 
were sequence-verified.
CRISPR-Cas9–based genome editing
To generate human myoblast cell lines expressing endogenously 
tagged AR45 for immunofluorescence studies, FLAG epitope tag 
was introduced to the N terminus of endogenous AR-2 gene in 
human myoblast cells via CRISPR-Cas9 genome editing strategy. A 
total of 5 × 105 human myoblast cells were transfected with 1.2 g of 
plasmid encoding both Cas9 protein and single-guided RNA targeting 
the start of AR-2 sequence and 0.8 g of plasmid containing the 
3× FLAG sequence flanked by 400–base pair (bp) arms of homology on 
either side of the insertion site. The latter served as DNA donor templates 
in the genome editing strategy, and it was synthesized by Invitrogen 
GeneArt Gene Synthesis service. Cas9-encoding pSpCas9(BB)-2A- 
GFP plasmid (px458) was a gift from F. Zhang (Addgene plasmid 
no. 48138). Transfection was performed by nucleofection using a 
Neon Transfection System (Thermo Fisher Scientific) following the 
manufacturer’s protocol. Cells were given three pulses of 1650 V for 
10 ms. Cells were then cultured for 48 hours in complete medium 
lacking antibiotic antimycotic. Transfected cells that expressed Cas9-
GFP were singularly sorted by fluorescence-activated cell sorting 
into 96-well culture dishes to establish clonal populations (Flow 
Cytometry Facility, Sir William Dunn School of Pathology, University 
of Oxford).
Luciferase report assays
To determine the effect of AR45 on AR-dependent transcriptional 
activity, HEK293T cells were transiently transfected with Lipofectamine 
2000 reagent (Invitrogen) in Opti-MEM I–reduced serum medium 
(Gibco) with 0.5 g of pARE-E1b-luc (luciferase report vector with 
an insertion of an ARE upstream of the luc2 gene), 0.5 g of pRL-TK 
(Renilla luciferase control) (Promega), and 0.5 g of AR FL and/or 
AR45 vector plasmids. Following 24 hours of transfection, cells 
were washed and treated with DHT or an equal volume ethanol as 
negative control. Cells were harvested after 24 hours and firefly and 
Renilla luciferase substrates (Dual-Luciferase Reporter Assay, Promega) 
were added, and luciferase activity was measured using a microplate 
spectrophotometer (CLARIOstar, BMG LabTech) according to the 
manufacturer’s protocol. Renilla luciferase activity was used as the 
internal normalization control.
NanoBRET assay
To investigate the interaction between AR FL protein and AR45 protein, 
NanoBRET assay was performed according to the manufacturer’s 
instructions (Promega NanoBRET Protein: Protein Interaction 
System). Briefly, HEK293T cells were cotransfected with a NanoLuc 
luciferase (Nluc) fusion plasmid and a HaloTag fusion plasmid with 
Lipofectamine 2000 reagent. A total of 200 ng of Nluc and 2000 ng 
of HaloTag fusion plasmid were used, unless otherwise stated. The 
combination of Nluc-MDM2 and p53-HaloTag was included as a 
positive control, and the combination of Nluc-MDM2 and HaloTag- 
SMAD4 was included as a negative control. At 24 hours after trans-
fection, cells were detached with TrypLE Express Enzyme (Gibco) 
and resuspended in Opti-MEM I–reduced serum medium, no phenol 
red (Gibco), supplemented with 4% (v/v) FBS. Cells were counted 
and seeded in triplicate into a 96-well microplate at 2 × 105 cells/ml. 
Cells were treated with or without 10 nM DHT. HaloTag NanoBRET 
618 ligand or dimethyl sulfoxide (DMSO) (no-ligand control) were 
added to each well at 1:1000 dilution. At 24 hours, NanoBRET 
Nano-Glo substrate was added to the cells, and NanoBRET readings at 
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(CLARIOstar, BMG LabTech). Mean-corrected NanoBRET ratios 
in milliBRET unit were calculated using the following formula:
Mean-corrected NanoBret ratio, milliBRET =.
[(618 nmEM / 460 nmEM)Experimental − (618 nmEM / 460 nmEM)
No-ligand control] × 1000.
Chromatin immunoprecipitation
AR45 ChIP was conducted on MCF7 cells transiently transfected 
with FLAG-AR45 plasmids. Untransfected MCF7 cells were included 
as the negative controls. Cells were treated with 10 nM DHT 24 hours 
after transfection. At 48 hours, cells were cross-linked with 1% 
formaldehyde for 10 min and harvested and lysed. Cell lysates were 
sonicated to an average DNA fragment length of 200 to 400 bp. The 
experiments were conducted as described (73) using 300 g of chromatin 
and 14 g of anti-FLAG antibody (Sigma-Aldrich, F1804) or anti 
mouse immunoglobulin G (IgG) antibody (Cell Signaling Technology, 
5415s). RNA Pol II ChIP was performed as described (74) on DHT- 
treated human myoblasts cells using Pol II antibody (2 l per IP; 
Santa Cruz Biotechnology, sc-9001). Purified DNA samples were used 
for quantitative real-time PCR. Oligonucleotides used for the PCR 
are available in table S4.
RNA and cDNA preparation and RT-qPCR
Ten milligrams of muscle, spinal cord, or liver tissues was homoge-
nized in 1-thioglycerol/homogenization solution for 2 × 1 min 
using Precellys tissue homogenizer (Bertin Instruments). Total 
RNA was isolated from murine tissues or cell lines using Maxwell 
RSC simplyRNA tissue or cells kit and Maxwell RSC Instrument 
(Promega) according to the manufacturer’s protocol. One microgram 
of RNA was used for cDNA synthesis with the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). RT-qPCR 
reactions were set up with fast SYBR green master mix or TaqMan 
gene expression master mix (Applied Biosystems) using 20 to 50 ng 
of DNA templates. The reactions were run with the default parameters 
of the Applied Biosystems Step One Plus real-time PCR system (for 
96-well format). AR45 differential expression in normal human 
tissues was detected by RT-qPCR using the TissueScan cDNA 
Array (Origene, HMRT104). Oligonucleotides used in the RT-qPCR 
experiments are listed in table S2.
AR45 siRNA screens and AR45 KD experiments
A panel of 11 siRNAs targeting all possible regions specific for AR45 
transcript and one nontargeting control siRNA (NTT) were designed 
and synthesized as described (75, 76). MCF7 cells were seeded and 
cultured at 105 cells/ml on 12-well dishes overnight in Dulbecco’s 
modified Eagle medium (DMEM) with GlutaMAX supplement (Gibco) 
supplemented with 10% FBS and 1× antibiotic antimycotic solution. 
One micromolar of siRNA-AR45 or siRNA-NTT was added to MCF7 
cells in 50:50 Opti-MEM I–reduced serum and DMEM cell culture 
medium in a final 3% (v/v) FBS. Total RNA was extracted from cells 
with TRIzol reagent according to the supplier’s protocol (Invitrogen). 
cDNA was prepared and RT-qPCR was performed as described in the 
previous section using FAM (Fluorescein amidites)-labeled TaqMan 
array Hs04272731_s1 specific for AR-1, Hs04275959_m1 specific for 
AR-2, and Hs99999905_m1 for GAPDH for normalization.
For AR45 KD experiments, human myoblasts were treated 
with 1 M AR45-targeting siRNA (SBMA-1) or NTT for 48 hours 
in 50:50 skeletal muscle growth medium/Opti-MEM I–reduced 
serum with 5% (v/v) FBS. DHT (10 nM) was added to the cells 
24  hours after transfection. siRNA sequences are available in 
fig. S5.
Generation of RNA-seq libraries
RNA was extracted from flash-frozen patient samples, cells, or 
murine tissues homogenized in TRIzol-chloroform and purified 
using the Ambion PureLink RNA Mini Kit or Qiagen RNeasy 
Mini Kit (74104, QIAGEN). RNA integrity was assessed using the 
Bioanalyzer (G2939BA, Agilent).
For the human tissues, RNA-seq libraries were prepared from 500 ng 
of total RNA using the KAPA Stranded RNA-seq Kit with RiboErase 
(Kapa Biosystems, 07962304001) for ribosomal RNA depletion and 
Illumina compatible indexes (NEXTflex RNA-seq Barcodes, NOVA-
512915, PerkinElmer). Pooled libraries (average insert size of 375 bp) 
were sequenced on an Illumina HiSeq 2500 platform using a paired-end 
125 nucleotide setting to yield 40 million to 50 million reads per 
library. For the iPSC-derived motor neurons, RNA-seq libraries were 
prepared from 500 ng of total RNA using the RNA-Seq Stranded 
RiboZero Gold. Sequencing was paired-end (2 × 75 bp) for target depth 
of 100 million read pairs per sample using the Illumina HiSeq 4000 
platform. Library preparation and sequencing were performed by the 
Bioinformatics Section, National Institute of Neurological Disorders 
and Stroke, National Institutes of Health (USA).
For the human myoblasts where AR45 was knocked down, 
mRNA libraries were generated using 1.5 g of total RNA and the 
NEBNext Ultra II Directional RNA Library Prep Kit for Illumina 
(New England BioLabs, E7760). Libraries were multiplexed and 
pair-end sequenced on the Illumina HiSeq 4000 platform. For the 
murine TA muscles, RNA-seq polyA libraries were prepared from 
900 ng of total RNA using the TruSeq Stranded mRNA kit (Illumina, 
20020595) and pair-end sequenced (2 × 150 bp) on the Illumina 
NovaSeq 6000 system. Library preparation and sequencing were 
performed by the Oxford Genomics Centre, The Wellcome Centre 
for Human Genetics, University of Oxford, England.
RNA-seq analysis pipeline
For the brain and iPSC dataset, paired-end sequence files (fastq) 
per sample were quality-inspected using the FastQC tool (www.
bioinformatics.babraham.ac.uk/projects/fastqc/), then adaptor-clipped 
(TruSeq3-PE-2.fa:2:30:10), and trimmed to remove 5′ nucleotide 
bias (HEADCROP:12) and low quality calls (TRAILING:20 
SLIDINGWINDOW:4:20 MINLEN:15) using the Trimmomatic tool 
(www.usadellab.org/cms/?page=trimmomatic). Surviving intact pairs 
of reads per sample were reference-mapped against the current 
instance of the human genome (GRCh38.82). Expression per known 
annotated gene (Homo_sapiens.GRCh38.82.chr.gtf) in transcripts per 
kilobase million units was pedestalled by 2 and then log2-transformed. 
Genes not having an expression value of >1 posttransformation for 
at least one sample were discarded as not detected, while expression 
across samples for genes not discarded was quantile normalized. To 
assure quality of the data postnormalization, exploratory inspection was 
performed using Tukey box plot, covariance-based principal compo-
nents analysis (PCA) scatterplot, and correlation-based heatmap. 
To remove noise-biased expression values, locally weighted scatterplot 
smoothing (LOWESS) was applied across normalized expression for 
all genes by sample class (coefficient of variation ~ mean expression). 
LOWESS fits were then overplotted and inspected to identify the 
common low-end expression value where the relationship between 
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“noise”) grossly deviated from linearity. Expression values were then 
floored to equal this value if less, while expression for genes not 
observed greater than this value for at least one sample was discarded 
as noise-biased. For genes not discarded, expression differences 
across sample classes were tested for using the one-factor analysis of 
variance (ANOVA) test under Benjamini-Hochberg (BH) false 
discovery rate multiple comparison correction condition using sample 
class as the factor. Genes having a type III–corrected P < 0.05 by this 
test were then subset and the TukeyHSD post hoc test used to 
generate mean differences and P values for each possible pairwise 
comparison of classes. Genes having a post hoc P < 0.05 for a specific 
comparison and a linear difference of means ≥1.5× for the same com-
parison were deemed to have expression significantly different 
between the compared classes respectively. After testing, sample-to- 
sample relationships were investigated via covariance-based PCA 
scatterplot and Pearson correlation–based clustered heatmap using 
the unique union of genes deemed to have a significant difference of 
expression between at least two classes.
For the human myoblasts and murine tissues dataset, sequence 
reads were adapted and quality trimmed with Trim Galore! (v 0.4.1; 
https://github.com/FelixKrueger/TrimGalore). Quality control on 
both raw and trimmed reads was done with FastQC (v 0.11.7; 
www.bioinformatics.babraham.ac.uk/projects/fastqc/) and MultiQC 
(v 0.9) (77). For human myoblasts datasets, trimmed reads were then 
aligned to the human reference transcriptome (Gencode v29; www.
gencodegenes.org/human/release_29.html) with Salmon (v 0.12) (78). 
The resulting quantification files were combined and read into R using 
the tximport package (v 1.12.3), and differential expression analysis 
was performed with DESeq2 (v 1.24) (79). For murine tissue datasets, 
trimmed reads were aligned to the mouse genome (Ensembl GRCm38) 
using HISAT2 (v 2.2.0) (80), alignment files were processed using 
SAMTools (v1.10) (81), and reads were counted in known genes 
(Mus_musculus.GRCm38.101.gtf) using the htseq-count function and –m 
union argument from HTSeq (v0.12.4) (82). Read counts files were com-
bined using Python, and differential expression analysis was performed 
using DESeq2. Differences between groups were tested using the 
DESeq2 contrast function, and BH-adjusted P values were reported.
Pathway analysis was performed on differentially expressed genes 
using the GSEA package (v 1.10.0) (83) with gene set permutation. 
Unless otherwise stated, all analysis was performed using default 
parameters. Heatmap was generated using the Multiple Experiment 
Viewer (v 4.8.1) (84). For murine tissues datasets, normalized 
counts were used to generate heatmap with k-means clustering 
(15 clusters each for up-regulated and down-regulated genes in the 
SBMA AR100Q samples). Clusters that showed reversed disease gene 
expression upon AAV9.AR45 treatment were combined to give lists 
of genes that were partially corrected by AR45 overexpression.
Motif scanning tool, Find Individual Motif Occurrences, was used 
to investigate the presence of ARE motif on the gene promoters (85). 
ARE motif or AR binding motif was obtained from JASPAR database, 
MA0007.2 for human AR binding sites, and MA0007.3 for mouse 
AR binding sites. Gene promoter was defined as region −1000 to +100 bp 
from RefSeq TSS. ggsashimi plot was generated using the scripts 
publicly available on GitHub with default parameters (86).
Cycloheximide chase assay
MCF7 cells were transfected with 1 g of FLAG-AR45 plasmid at 
40% confluency. Eight hours after transfection, cells were treated 
with 10 nM DHT or equal volume ethanol. After 12 hours, 100 g 
of cycloheximide in DMSO (Sigma-Aldrich) was added to the cells 
(t = 0) and cells were harvested at 0 and 24 hours for protein expression 
analysis. Untransfected MCF7 cells with cycloheximide treatment 
were included for comparisons.
Immunoblotting ELISA
Cells were lysed in 2×  SDS–polyacrylamide gel electrophoresis 
(SDS-PAGE) buffer [4% (w/v) SDS, 100 mM tris-base, 20% (v/v) 
glycerol, and 0.008% (w/v) bromophenol blue] supplemented with 
PhosSTOP and cOmplete, mini, EDTA-free protease inhibitor cocktail 
(Roche) at 4°C. Lysates were boiled at 100°C for 10 min before centrif-
ugation. Supernatants were collected, and protein levels were measured 
and adjusted by Pierce BCA Protein Assay (Thermo Fisher Scientific). 
For Western blot analysis, proteins were separated on NuPAGE 10% 
bis-tris gel (Invitrogen) and transferred onto polyvinylidene difluoride 
membranes using Invitrogen Novex XCell SureLock Mini-Cell and 
XCell II blot module. Membranes were incubated overnight with 
primary antibody in 1:1000 dilution, anti-AR antibody (Santa Cruz 
Biotechnology, H-280 or Abcam, ab52615), anti-tubulin (Thermo 
Fisher Scientific, 14-4502-82), or anti-vinculin (Sigma-Aldrich, hVIN-1) 
and, for 1 hour with secondary antibody in 1:10,000 dilution, anti–mouse- 
horseradish peroxidase (HRP)–conjugated antibody (Invitrogen, 
62-6520) or anti–rabbit-HRP conjugated antibody (Invitrogen, 31460). 
Protein signals were detected in the presence of Pierce ECL Western 
blotting substrate (Thermo Fisher Scientific) using LI-COR Odyssey 
Infrared Imaging System. For cycloheximide chase experiments, 
quantifications were performed using the ImageStudio software 
(Li-Cor Biosciences).
For FLAG-AR45 co-IP experiments, cells were lysed with lysis buffer 
[50 mM tris-HCl, 0.1 M NaCl, 1% (v/v) NP-40, and 10% (v/v) glycerol 
(pH 7.5)] supplemented with protease inhibitor cocktail (Roche) at 
4°C. Lysate was cleared by centrifugation, and the supernatant was pre-
cleared through incubation with protein G agarose beads (Invitrogen). 
The supernatant was then incubated overnight at 4°C with mono-
clonal anti-FLAG M2–conjugated magnetic beads (Sigma-Aldrich, 
M8823), or untagged beads (Chromotek bab-20), as a control. Beads 
were washed three times with wash buffer [0.1 M tris-HCl, 0.3 M 
NaCl, and 1% (v/v) Triton X-100 (pH 7.5)], which was followed by 
elution with 1× sample buffer, separation on SDS-PAGE gels, and 
analysis by Western blotting following standard protocols.
For AR co-IP experiments to assess AR interaction with BRD4, cells 
were lysed and nuclear fractions were obtained using NE-PERTM nuclear 
and cytoplasmic extraction kit following the manufacturer’s protocol 
(Thermo Fisher Scientific). One microgram of mouse monoclonal anti-AR 
antibody (Santa Cruz Biotechnology, 441, sc-7305) or monoclonal anti- 
mouse IgG1 isotype control antibody (Cell Signaling Technology, 5415s) 
was coupled to protein G magnetic Dynabeads (Invitrogen). Nuclear 
extracts were incubated overnight at 4°C with the antibody- conjugated 
beads. Beads were washed for 10 times in 1% PBS with Tween 20, 
followed by elution in 2× SDS protein gel loading buffer at 100°C 
for 10 min and separation on SDS-PAGE gels and Western blotting.
Serum testosterone levels in AR45- versus mock-treated AR100Q 
mice at 11 weeks of age were measured using the Testosterone 
Parameter Assay Kit (R&D Systems, KGE010) according to the 
manufacturer’s protocol.
Immunofluorescence and immunohistochemistry
Spinal cord and quadriceps muscle tissues were dissected and 
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were stained with H&E or NADH to ascertain the overall morphology 
and pathologic changes. For immunofluorescence experiments, cross 
sections of spinal cord, quadriceps muscle, TA muscle, and liver 
tissues were permeabilized in 0.1% Triton X-100 and blocked in 
PBS with 4% bovine serum albumin and 2% normal goat serum. 
Sections were incubated overnight at 4°C in 1:100 dilution with anti- 
NCAM (ProteinTech, 14255-1-AP), anti–P-NCAM (EMD Millipore, 
5324), anti-ubiquitin (Abcam, ab7780), anti-laminin (Sigma-Aldrich, 
L0663), anti-ChAT (Novusbio, NBP1-30052), or anti-F4/80 (Abcam, 
ab131260) antibodies followed by incubation for 1 hour (20° to 25°C) 
with the appropriate Alexa Fluor–conjugated secondary antibodies 
(1:1000; Thermo Fisher Scientific). Sections were mounted with the 
VECTASHIELD Antifade Mountant with 4′,6-diamidino-2- 
phenylindole (DAPI) (Vector Laboratories) and allowed to dry for 
at least 24 hours at (20° to 25°C) before imaging. To determine the 
number of inclusions, tissue sections were stained with 1C2 antibody 
(1:5000; EMD Millipore, 5TF1-1C2) using the Mouse on Mouse Basic 
Kit (Vector Laboratories, BMK-2202). For the purposes quantification, 
whole slides containing six sections of tissue 50 m apart from three 
different animals were imported into the 3D Histec Pannoramic 
250 slide scanner (3D Histech, Hungary). This was performed at 
Bioimaging Facility, University of Manchester. Images from at least 
four contiguous sections were taken using the CaseViewer software 
and analyzed by a blinded investigator to the treatment using Fiji 
software (87).
To detect FL-AR45 protein via immunofluorescence, human 
myoblast cells grown on poly-l-lysine–coated cover slips, sections 
of spinal cord, and TA muscles of AR100Q mice were fixed in 
cooled methanol for 10 min at −20°C and then in cooled acetone for 
1 min at −20°C. Sections or cells were incubated overnight at 4C in 
1:80 dilution with rabbit anti-FLAG (Sigma-Aldrich, F7425) antibody 
followed by incubation for 1 hour at room temperature with secondary 
anti-rabbit IgG Alexa Fluor 555 antibody (Invitrogen, A21428) at 
1:1000 dilution and DAPI staining for 3 min. Sections or cells were 
mounted with DAKO fluorescence mounting medium (DAKO, s3023) 
and imaged with the EVOS FL Auto Imaging System (Thermo Fisher 
Scientific) or the 3D Histec Pannoramic 250 slide scanner.
Statistical analyses
Survival and time to disease onset of SBMA mice were determined 
by Kaplan-Meier estimation, and comparisons were made with the 
log-rank test. A two-way ANOVA was conducted to compare the 
effect of the treatment on weights, rotarod performances, and grip 
strength of the animals using treatment as a between-subjects factor 
and time as a within-subjects factor. All other data were analyzed by 
a two-tailed t test analysis. GraphPad Prism version 8 was used to 
perform the statistical analyses. Power analysis was performed using 
G*Power 3.1.9.2 software.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/34/eabi6896/DC1
View/request a protocol for this paper from Bio-protocol.
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